{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}],"title":"High Risk"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"24"}]}],"title":"Standard Risk"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}],"title":"Low Risk"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"37"}],"units":"Participants"}],"description":"Plasma cell myeloma cytogenetic subtype was assessed at the screening visit using standard karyotyping and/or fluorescence in situ hybridization. The number of participants in each cytogenetic risk category are provided: High Risk (International Staging System \\[ISS\\] stage II or III and t(4;14) or del(17p) abnormality); Standard Risk (not high or low risk); and Low Risk (ISS stage I or II and absence of t(4;14), del(17p) and 1q21 abnormalities AND age \\< 55).","groups":[{"description":"Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG000","title":"Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG001","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG002","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG003","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG004","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"}],"paramType":"NUMBER","populationDescription":"Safety population: All randomized participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Screening (up to 14 days prior to dosing)","title":"Plasma Cell Myeloma Cytogenetic Subtype","type":"SECONDARY","unitOfMeasure":"participants"}